Beijing Konruns Pharmaceutical Co Ltd - Asset Resilience Ratio
Beijing Konruns Pharmaceutical Co Ltd (603590) has an Asset Resilience Ratio of 11.89% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Beijing Konruns Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Beijing Konruns Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See net assets of Beijing Konruns Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Beijing Konruns Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beijing Konruns Pharmaceutical Co Ltd (603590) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥481.36 Million | 11.89% |
| Total Liquid Assets | CN¥481.36 Million | 11.89% |
Asset Resilience Insights
- Moderate Liquidity: Beijing Konruns Pharmaceutical Co Ltd has 11.89% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beijing Konruns Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Konruns Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Beijing Konruns Pharmaceutical Co Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Beijing Konruns Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.50% | CN¥450.66 Million ≈ $65.95 Million |
CN¥3.92 Billion ≈ $573.57 Million |
+1.01pp |
| 2023-12-31 | 10.48% | CN¥396.41 Million ≈ $58.01 Million |
CN¥3.78 Billion ≈ $553.25 Million |
+2.30pp |
| 2022-12-31 | 8.19% | CN¥280.37 Million ≈ $41.03 Million |
CN¥3.42 Billion ≈ $501.16 Million |
+7.92pp |
| 2021-12-31 | 0.27% | CN¥9.04 Million ≈ $1.32 Million |
CN¥3.37 Billion ≈ $493.33 Million |
-4.52pp |
| 2020-12-31 | 4.79% | CN¥181.36 Million ≈ $26.54 Million |
CN¥3.79 Billion ≈ $553.96 Million |
+4.73pp |
| 2019-12-31 | 0.06% | CN¥2.00 Million ≈ $293.16K |
CN¥3.17 Billion ≈ $464.43 Million |
-- |
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more